CAMP4 Raises $97.5M, Wins $17.5M GSK Upfront, Plans H2 2026 Phase 1/2 for CMP-002
CAMP4 ended 2025 with $109.5M cash and extended runway into 2028 after $50M private placement, $30M stock offering and $17.5M GSK upfront in RNA collaboration valued up to $440M. GLP toxicology for CMP-002 is ongoing with a global Phase 1/2 SYNGAP1 trial expected in H2 2026.
1. Strategic Collaboration with GSK
CAMP4 entered a research, collaboration and license agreement with GSK to discover and develop antisense oligonucleotide candidates for neurodegenerative and kidney disease targets. The company received a $17.5 million upfront payment and is eligible for up to $440 million in development and commercial milestones, plus tiered royalties.
2. Financing and Cash Position
In 2025 CAMP4 completed a $50 million private placement with potential for an additional $50 million and a $30 million underwritten common stock offering. Total cash and equivalents rose to $109.5 million at year-end, providing funding into 2028.
3. CMP-002 Development Progress
GLP toxicology studies for lead candidate CMP-002 are underway to support regulatory filings. CAMP4 expects to initiate a global first-in-human Phase 1/2 trial in SYNGAP1 patients in the second half of 2026.
4. 2025 Financial Results
Research and development expenses were $38.2 million, down slightly from $38.8 million, while general and administrative costs rose to $17.4 million from $14.9 million. Net loss widened to $80.4 million due to a $29.8 million non-cash derivative liability adjustment.